Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Community-Acquired Bacterial Pneumonia (CABP)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Community-Acquired Bacterial Pneumonia (CABP). Displaying page 1 of 1.
    EudraCT Number: 2015-003026-14 Sponsor Protocol Number: ML-3341-306 Start Date*: 2016-02-04
    Sponsor Name:Melinta Therapeutics, Inc.
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTE...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) LV (Completed) BG (Completed) DE (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002986-32 Sponsor Protocol Number: PTK0796-CABP-19302 Start Date*: 2020-10-26
    Sponsor Name:Paratek Pharmaceuticals, Inc.
    Full Title: A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial ...
    Medical condition: Community-Acquired Bacterial Pneumonia (CABP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HR (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003971-20 Sponsor Protocol Number: CE01-300 Start Date*: 2013-05-07
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Ac...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) PL (Completed) LV (Completed) EE (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002182-35 Sponsor Protocol Number: P903-25 Start Date*: 2012-10-22
    Sponsor Name:Cerexa, Inc. (subsidiary of Forest Laboratories)
    Full Title: A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects with Community-acquired ...
    Medical condition: Community-acquired bacterial pneumonia (CABP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003453-13 Sponsor Protocol Number: CE01-301 Start Date*: 2014-06-18
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Ad...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) LV (Completed) DE (Completed) ES (Completed) RO (Completed) SK (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2013-004071-13 Sponsor Protocol Number: PTK0796-CABP-1200 Start Date*: 2015-05-20
    Sponsor Name:Paratek Pharma LLC
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial P...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) LV (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Prematurely Ended) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002203-18 Sponsor Protocol Number: P903-31 Start Date*: 2012-07-18
    Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories)
    Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With...
    Medical condition: Community-acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035664 Pneumonia PT
    14.1 10021881 - Infections and infestations 10004051 Bacterial pneumonia, unspecified LLT
    14.1 10021881 - Infections and infestations 10060946 Pneumonia bacterial PT
    14.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-002683-32 Sponsor Protocol Number: DUR001-305 Start Date*: 2015-03-30
    Sponsor Name:Durata Therapeutics International B.V.
    Full Title: A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia
    Medical condition: Community acquired bacterial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004039-37 Sponsor Protocol Number: CE01-203 Start Date*: 2014-10-10
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients ...
    Medical condition: suspected or confirmed community acquired bacterial pneuumonia (CABP)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (Completed) HU (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2016-001246-26 Sponsor Protocol Number: W-4873-201 Start Date*: 2016-10-07
    Sponsor Name:Wockhardt Bio AG
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treat...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021574-11 Sponsor Protocol Number: 32729463CAP2001 Start Date*: 2011-01-24
    Sponsor Name:Furiex Pharmaceuticals, Inc
    Full Title: A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospita...
    Medical condition: Community-Acquired Bacterial Pneumonia (CABP)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-004782-92 Sponsor Protocol Number: NAB-BC-3781-3102 Start Date*: 2016-07-26
    Sponsor Name:Nabriva Therapeutics AG
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia
    Medical condition: Community-acquired bacterial pneumonia (CABP) is a commonly occurring serious infection that requires systemic antibiotic therapy and is associated with substantial morbidity, mortality, and consid...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-005169-63 Sponsor Protocol Number: NAB-BC-3781-3101 Start Date*: 2016-01-12
    Sponsor Name:Nabriva Therapeutics AG
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) LV (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002994-39 Sponsor Protocol Number: Cx611-0204 Start Date*: 2016-04-06
    Sponsor Name:TIGENIX, S.A.U.
    Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for...
    Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 05:29:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA